Awaiting development: Guidance and quality standards

Showing 11 to 20 of 344

Guidance and quality standards awaiting development
Title	Type
Allo-APZ2-CVU for treating chronic venous leg ulcers [ID6754]	Technology appraisal guidance
Allo-APZ2-EB for treating dystrophic and junctional epidermolysis bullosa in people of any age [ID6746]	Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]	Technology appraisal guidance
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [ID6664]	Technology appraisal guidance
Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [GID-TA12005]	Technology appraisal guidance
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]	Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]	Technology appraisal guidance
Apraglutide for treating short bowel syndrome [ID6533]	Technology appraisal guidance
Aprocitentan for treating resistant hypertension [ID6681]	Technology appraisal guidance
Asundexian for preventing stroke after acute non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack [GID-TA12033]	Technology appraisal guidance